

H-A

03Co

CEDAR-45257

#4

Date Mailed: April 13, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Anthony P. Heaney, Gregory A. Horwitz, Xun Zhang, and Shlomo Melmed
Serial No. 09/730,469
Filed: December 4, 2000
For: METHODS OF USING PITUITARY TUMOR TRANSFORMING GENE (PTTG) CARBOXY-TERMINAL PEPTIDES TO INHIBIT NEOPLASTIC CELLULAR PROLIFERATION AND/OR TRANSFORMATION OF BREAST AND OVARIAN CELLS
Examiner: Unknown
Unit: --

Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D. C. 20231, ON APRIL 13, 2001
BY ANN WEISS
APRIL 13, 2001
(DATE OF SIGNATURE)

Applicant's attorney submits herewith copies of the patents and/or other literature of which he is aware, that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicant's attorney further submits herewith Form PTO-1449, "Information Disclosure Statement" by Applicant. A copy of each of the disclosed patents and other references listed as other documents Nos. 1-52 are not being submitted herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited by the Examiner and/or the Applicant in connection with related applications U.S. Serial No. 08/894,251, filed July 23, 1999; U.S. Serial No. 09/569,956 filed May 12, 2000, and U.S. Serial No. 09/687,911, filed October 13, 2000. These previously filed

Date Mailed: April 13, 2001



Applications were cited by applicant in this present Application per 35 U.S.C. §§ 120 and 119(e).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this information disclosure statement is being filed before the mailing of a first office action on the merits.

The Commissioner is hereby authorized to credit overpayments or charge any fees required under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 50-1597.

Respectfully submitted,

By:

Nisan A. Steinberg, Ph.D.
Registration No. 40,345

SIDLEY & AUSTIN
555 West Fifth Street
Los Angeles, California 90013-1010
Ofc: 213/ 896-6665
Fax: 213/896-6600